This is a preview of subscription content, log in via an institution to check access.
Notes
Rivaroxaban Once Daily Direct Factor Xa inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in AF
The study was sponsored by Bayer-Hellas.
Reference
Kourlaba G, et al. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Effectiveness and Resource Allocation : 10 Feb 2014. Available from: URL: http://dx.doi.org/doi:10.1186/1478-7547-12-5
Rights and permissions
About this article
Cite this article
Rivaroxaban more effective, less costly for stroke prevention in AF. PharmacoEcon Outcomes News 697, 8 (2014). https://doi.org/10.1007/s40274-014-1076-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1076-8